EGFR and non-small cell lung carcinoma: EGFR is currently an important target for targeted therapy of NSCLC; thus, the study of PTMs of EGFR can provide a basis for the discovery of potential glycosylation-related targets in EGFR-TKI therapy for NSCLC.